BioWorld

Feb. 2, 2005

View Archived Issues

Angiogenix Rethinking Acclaim Formulation After Phase II Miss

Read More

Northwest Biotherapeutics Cleared For Phase III Study

Read More

Arena Raises $45M With Plans To Advance GPCR Candidates

Read More

Other News To Note

Read More

Manufacturing Issue Slows Down Timeline For Decision On Surfaxin

Drug manufacturing issues caused investors to dump shares of Discovery Laboratories Inc., dropping the company's stock price by 22 percent Tuesday. (BioWorld Today) Read More